The secondary objectives are – with reference to the ADA criteria for classification of hypoglycaemia [26] – to evaluate the effects of insulin analogue and human insulin from 3 to 12 months of treatment on the incidence of:. This evidence concerns the gene INS and Hypoglycemia.